Efficacy of enfortumab vedotin in populations of interest among patients with advanced urothelial cancer

被引：1
|
作者：
Koshkin, V. S. [1 ]
Sun, Y. [2 ]
Osterman, C. K. [3 ]
Natesan, D. [4 ]
Su, C. [5 ]
Lemke, E. [6 ]
Khaki, A. R. [7 ]
Johnson, A. [8 ]
Owens, X. [9 ]
Park, J. J. [5 ]
Basu, A. [9 ]
Barata, P. M. Coelho [8 ]
Davis, N. [10 ]
Grivas, P. [11 ]
Milowsky, M. [3 ]
Kilari, D. [6 ]
Alva, A. [5 ]
机构：
[1] UCSF, Helen Diller Family Comprehens Canc Ctr, Dept Med, Div Med Oncol, San Francisco, CA USA
[2] Univ Michigan, Biostat, Ann Arbor, MI USA
[3] Univ N Carolina, Med, Chapel Hill, NC 27515 USA
[4] UCSF, Helen Diller Family Comprehens Canc Ctr, Genitourinary Med Oncol, San Francisco, CA USA
[5] Univ Michigan, Med, Ann Arbor, MI 48109 USA
[6] Med Coll Wisconsin, Med, Milwaukee, WI 53226 USA
[7] Univ Washington, Med, Seattle, WA 98195 USA
[8] Tulane Univ, Dept Med Oncol, New Orleans, LA 70118 USA
[9] Univ Alabama Birmingham, Med, Birmingham, AL USA
[10] Vanderbilt Univ, Med Ctr, Med, Nashville, TN USA
[11] Univ Washington, Seattle Canc Care Alliance, Hematol Oncol, Seattle, WA 98195 USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.843
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
771P
引用
收藏
页码：S594 / S594
页数：1
相关论文
共 50 条
  • [21] Enfortumab Vedotin for Elderly Advanced Urothelial Carcinoma Patients or Those With a Poor Performance Status
    Furubayashi, Nobuki
    Minato, Akinori
    Tomoda, Toshihisa
    Masaoka, Hiroyuki
    Hori, Yoshifumi
    Kiyoshima, Keijiro
    Negishi, Takahito
    Haraguchi, Yusuke
    Koga, Toshiki
    Song, Yoohyun
    Harada, Kenichi
    Kuroiwa, Kentaro
    Seki, Narihito
    Fujimoto, Naohiro
    Nakamura, Motonobu
    ANTICANCER RESEARCH, 2024, 44 (08) : 3409 - 3417
  • [22] Managing potential adverse events during treatment with enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer
    Brower, Blaine
    Mccoy, Asia
    Ahmad, Hiba
    Eitman, Cheryl
    Bowman, I. Alex
    Rembisz, Jennifer
    Milowsky, Matthew I.
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [23] First Evidence of Activity of Enfortumab Vedotin on Brain Metastases in Urothelial Cancer Patients
    Vulsteke, Christof
    De Cocker, Laurens
    de Liano, Alfonso Gomez
    Montesdeoca, Cristina
    De Meulenaere, Astrid
    Croes, Lieselot
    Delombaerde, Danielle
    Szabados, Bernadett
    Powles, Thomas
    PHARMACEUTICALS, 2023, 16 (03)
  • [24] Safety and efficacy of enfortumab vedotin in patients with metastatic/locally advanced urothelial cancer: Real-world evidence from a European database.
    Zschaebitz, Stefanie
    Kluemper, Niklas
    Holzwarth, Nina
    Biernath, Nadine
    Hoellein, Alexander
    Niegisch, Guenter
    Seidl, Daniel
    Aydogdu, Can
    Handke, Analena
    Paffenholz, Pia
    Schlack, Katrin
    Cathomas, Richard
    Erne, Eva
    Banek, Severine
    Tauber, Robert
    Casuscelli, Jozefina
    Seitz, Anna Katharina
    Gruenwald, Viktor
    Darr, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 553 - 553
  • [25] Comparison of the efficacy of enfortumab vedotin and paclitaxel plus carboplatin in patients with metastatic urothelial carcinoma
    Nakagawa, Ryunosuke
    Izumi, Kouji
    Toriumi, Ren
    Aoyama, Shuhei
    Kano, Hiroshi
    Makino, Tomoyuki
    Naito, Renato
    Kadomoto, Suguru
    Iwamoto, Hiroaki
    Yaegashi, Hiroshi
    Kawaguchi, Shohei
    Nohara, Takahiro
    Shigehara, Kazuyoshi
    Mizokami, Atsushi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2025, 30 (03) : 524 - 531
  • [26] A CASE OF ENFORTUMAB VEDOTIN TOXICITY IN A PATIENT WITH ADVANCED UROTHELIAL CELL CARCINOMA
    Grigsby, Charles
    Thebert, Alexander
    Pijut, Kyle
    Woodward, Blake
    Bastin, Melissa Thompson
    Soper, Melissa
    Fozzard, Andrew
    CRITICAL CARE MEDICINE, 2024, 52
  • [27] Impact of Relative Dose Intensity of Enfortumab Vedotin for Advanced Urothelial Carcinoma
    Furubayashi, Nobuki
    Negishi, Takahito
    Mochida, Manabu
    Kijima, Atsuhiro
    Katsuki, Harumichi
    Nakamura, Motonobu
    IN VIVO, 2025, 39 (01): : 411 - 418
  • [28] ASSOCIATION BETWEEN CUTANEOUS REACTIONS RELATED TO ENFORTUMAB VEDOTIN AND SERUM ALBUMIN LEVELS IN PATIENTS WITH ADVANCED UROTHELIAL CANCER
    Yamamoto, Hayato
    Yoneyama, Fumiya
    Ishii, Noritaka
    Soma, Osamu
    Fujita, Naoki
    Okamoto, Teppei
    Yoneyama, Takahiro
    Hatakeyama, Shingo
    JOURNAL OF UROLOGY, 2024, 211 (05): : E873 - E873
  • [29] Therapeutic efficacy and safety of biweekly administration of enfortumab vedotin for urothelial carcinoma
    Nakagawa, Ryunosuke
    Izumi, Kouji
    Toriumi, Ren
    Aoyama, Shuhei
    Kamijima, Taiki
    Kano, Hiroshi
    Makino, Tomoyuki
    Naito, Renato
    Iwamoto, Hiroaki
    Yaegashi, Hiroshi
    Kawaguchi, Shohei
    Shigehara, Kazuyoshi
    Nohara, Takahiro
    Mizokami, Atsushi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (12) : 1329 - 1335
  • [30] Enfortumab vedotin - next game-changer in urothelial cancer
    Maas, Moritz
    Stuehler, Viktoria
    Walz, Simon
    Stenzl, Arnulf
    Bedke, Jens
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 801 - 809
12345